Rifaximin 550 milligram Oral Tablet [XIFAXAN]

DRUG2 trials

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Samar Atef Sebaweh Mohammed

Conditions

Ascites InfectionCirrhosis, LiverHepatic EncephalopathyLiver DiseasesPathological ProcessesPortal Hypertension

Phase 2

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

CompletedNCT05621005

Samar Atef Sebaweh MohammedAscites Infection

Start: 2019-03-01End: 2022-08-01Updated: 2022-11-21

Phase 4

Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose

RecruitingNCT04073290

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Cirrhosis, Liver, Hepatic Encephalopathy, Liver Diseases +2

Start: 2020-01-21End: 2026-12-31Target: 238Updated: 2025-01-28

Related Papers

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)

BMJ Open Gastroenterology2020-12-0140 citations